LEADER 02517nam 22006373 450 001 9910876579603321 005 20220610194715.0 010 $a0-470-84635-6 010 $a9786610554881 010 $a1-280-55488-6 035 $a(OCoLC)85820010 035 $a(CKB)111056485557306 035 $a(MiAaPQ)EBC4956309 035 $a(Au-PeEL)EBL4956309 035 $a(CaONFJC)MIL55488 035 $a(OCoLC)1024259038 035 $a(EXLCZ)99111056485557306 100 $a20210901d2003 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug resistance in epilepsy 205 $a1st ed. 210 1$aNew York :$cWiley,$d2003. 210 4$dİ2003. 215 $a1 online resource (254 pages) 225 1 $aNovartis Foundation Symposia ;$vv.Vol. 243 311 $a0-470-84146-X 311 $a0-470-85189-9 330 $aThe object of this book is to gather together workers in the fields of epilepsy, those concerned with the basic science of resistance and the blood-brain barrier, and those with clinical experience of drug resistance in cancer, with a view to stimulating further work on drug resistance in epilepsy. Whilst resistance in cancer has been extensively studied, and trials of reversal of resistance have been undertaken, with some success, resistance in epilepsy has only just begun to be addressed. 410 0$aNovartis Foundation Symposia 517 $aMechanisms of Drug Resistance in Epilepsy 517 $aDrug Resistance in Epilepsy 517 $aNovartis Foundation Symposium 243 - Mechanisms of Drug Resistance in Epilepsy - Lessons from Oncology 606 $aEpilepsy$xdrug therapy 606 $aATP Binding Cassette Transporter, Subfamily B$xmetabolism 606 $aDrug Resistance 608 $aCongress. 615 12$aEpilepsy$xdrug therapy. 615 22$aATP Binding Cassette Transporter, Subfamily B$xmetabolism. 615 22$aDrug Resistance. 676 $a616.853061 700 $aFoundation$b Novartis$01751415 701 $aBock$b Gregory$0322650 701 $aGoode$b Jamie$0283336 712 02$aNovartis Foundation. 712 12$aSymposium on Mechanisms of Drug Resistance in Epilepsy : Lessons from Oncology$f(2001 :$eLondon, England) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910876579603321 996 $aDrug resistance in epilepsy$94186370 997 $aUNINA